Skip to content
Menu

RedHill Biopharma Ltd. RDHL

Full chart Compare
Set alert

Price alert · RDHL

All alert types
0.28 USD -0.04 (-13.08%)

Regular-session close

0.29 0.00 +1.78%

After hours · Nov 20, 4:00 PM ET

0.281 Day range 0.3385
0.281 52-week range 1.40
YTD
-72.72%
1 year
-72.98%

5D -0.0200 (-5.41%)

0.32500.35000.37500.4000ThuFriMonTueWed0.3500
Market cap
2.50M
Revenue (ttm)
3.71M
Shares out
1.28M
Forward P/E
210.67
YTD return
-72.72%
1-year return
-72.98%
50-day average
7.70
Volume
24.25K
Avg volume
2.08M
Open
0.3114
Previous close
0.3233
Day's range
0.281 – 0.3385
52-week range
0.281 – 1.40
Beta
3.67

Key statistics

200-day average
9.87
Enterprise value
76.44B
Price / sales
2.18
Price / book
121.54
Revenue growth
-28.40%
Free cash flow
-5.39M
Total cash
7.28M
Total debt
558.00K
Return on equity
-1708.61%
Short % of float
0.49%

Fundamental scorecard

2 of 25 checks passed on RDHL’s reported financials

ValueGrowthProfitabilityHealthDividend

2of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
RDHL Revenue — quarterly 1.80M
RDHL Net income — quarterly 761.00K
RDHL EPS — quarterly -100.00

Earnings

RDHL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Oct 3, 2024Jun 1, 20240.00———
Jul 1, 2024Mar 1, 20240.00———
Jan 2, 2024Sep 1, 20230.00———
Jun 12, 2023Mar 1, 20230.00146.75——

About RedHill Biopharma Ltd.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Israel

News

Your note

Sign in to keep a note on RDHL — it syncs with the Stock Master app.

Institution ownership

RDHL institution ownership
Holder% heldSharesValueReported
Federation Des Caisses Desjardins Du Quebec0.31%3,99225.23KSep 29, 2024
Rhumbline Advisers0.08%9796.19KSep 29, 2024
Osaic Holdings Inc0.03%3962.50KSep 29, 2024
Morgan Stanley0.01%1801.14KSep 29, 2024
Capital Performance Advisors LLP0.00%531Sep 29, 2024
Group One Trading, L.P.0.00%22139Sep 29, 2024

Fund ownership

RDHL fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.00%41259Sep 29, 2024